search
Back to results

Improving Medication Adherence in Post-ACS Patients

Primary Purpose

Medication Adherence, Acute Coronary Syndrome

Status
Terminated
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
PST therapy
Sponsored by
Columbia University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Medication Adherence focused on measuring medication adherence

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Medical eligibility:

    1. Patient presenting for staged intervention with positive cardiac history OR
    2. Patient with stable CAD who received cardiac admission but does not report chest pain. OR
    3. Patient with stable CAD who has had a cardiac admission in the past.
  2. Patient is non-adherent to prescribed medication.

The following exclusion criteria have been set for either safety concerns or concerns that patients will not be able to complete the protocol:

  1. inability to communicate in English or Spanish
  2. unwilling to be randomized or to have aspirin in a separate bottle if they use a pill box
  3. unavailability for the 1 month period of the study (including being unavailable by phone and/or traveling out of the country)
  4. medically unable to receive aspirin (e.g. allergy, contra-indicated, etc)
  5. deemed unable to comply with the protocol (either self selected or by indicating during screening that s/he could not complete all requested tasks). This includes patients with a level of cognitive impairment indicative of dementia, and patients with current alcohol or substance abuse.
  6. deemed to need immediate psychiatric assessment (e.g., must be hospitalized, or have some other psychiatric intervention conducted within 72 hours).
  7. active psychosis, bipolar disorder, or any overt personality disorder

Sites / Locations

  • Columbia University

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

A

B

Arm Description

Participants will complete Baseline and 30-day assessment visit. At both visits BDI II, Self-Efficacy Questions, AEs Assessment, and Treatment Satisfaction will be assessed. A MEMS cap will be used during the 30-day period to asses medication adherence to their prescribed aspirin. Usual Care: Participants assigned to UCC will only receive the pre- and post-assessment session, and any adherence education or encouragement that is regularly provided by their treating physicians.

Participants will complete Baseline and 30-day assessment visit. At both visits BDI II, Self-Efficacy Questions, AEs Assessment, and Treatment Satisfaction will be assessed. A MEMS cap will be used during the 30-day period to asses medication adherence to their prescribed aspirin. After Baseline, there is an initial session telephone session with PST therapist. Subsequent treatment sessions provide a context for the patient to discuss the problems and difficulties they face and that give rise to medication non-adherence.

Outcomes

Primary Outcome Measures

Prevalence of medication adherence

Secondary Outcome Measures

Full Information

First Posted
December 14, 2007
Last Updated
May 13, 2015
Sponsor
Columbia University
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
search

1. Study Identification

Unique Protocol Identification Number
NCT00576160
Brief Title
Improving Medication Adherence in Post-ACS Patients
Official Title
Improving Med Adherence in Post-ACS Patients: Phase 1B Dose-Finding RCT
Study Type
Interventional

2. Study Status

Record Verification Date
May 2015
Overall Recruitment Status
Terminated
Why Stopped
This was a dosing study to determine acceptability. Participants found protocol burdensome and so we terminated.
Study Start Date
August 2007 (undefined)
Primary Completion Date
June 2011 (Actual)
Study Completion Date
June 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Columbia University
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Many post Acute Coronary Syndrome(ACS) patients do not take their medications (including aspirin) as prescribed, leading to an increase in mortality. Patients enrolled in this study will be enrolled into one of two groups. Patients in the first group will have their medication adherence measured, but will receive all other care as usual. Patients in the second group will also have their medication adherence measured, but they will receive telephone-delivered problem solving therapy (PST) in addition to their usual care. The two groups will be combined to determine the Minimally Effective Dose (MED) and the Maximally Tolerated Dose (MTD) for adherence to aspirin. The medication adherence of the PST group will improve by 20% (<55% to >75%).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Medication Adherence, Acute Coronary Syndrome
Keywords
medication adherence

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
22 (Actual)

8. Arms, Groups, and Interventions

Arm Title
A
Arm Type
No Intervention
Arm Description
Participants will complete Baseline and 30-day assessment visit. At both visits BDI II, Self-Efficacy Questions, AEs Assessment, and Treatment Satisfaction will be assessed. A MEMS cap will be used during the 30-day period to asses medication adherence to their prescribed aspirin. Usual Care: Participants assigned to UCC will only receive the pre- and post-assessment session, and any adherence education or encouragement that is regularly provided by their treating physicians.
Arm Title
B
Arm Type
Experimental
Arm Description
Participants will complete Baseline and 30-day assessment visit. At both visits BDI II, Self-Efficacy Questions, AEs Assessment, and Treatment Satisfaction will be assessed. A MEMS cap will be used during the 30-day period to asses medication adherence to their prescribed aspirin. After Baseline, there is an initial session telephone session with PST therapist. Subsequent treatment sessions provide a context for the patient to discuss the problems and difficulties they face and that give rise to medication non-adherence.
Intervention Type
Behavioral
Intervention Name(s)
PST therapy
Intervention Description
Problem-Solving Therapy (PST) is a behavioral approach that teaches patients how to systematically solve their own behavioral difficulties. During telephone treatment sessions, the patient will discuss the problems and difficulties they face and that give rise to medication non-adherence.
Primary Outcome Measure Information:
Title
Prevalence of medication adherence
Time Frame
30 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Medical eligibility: Patient presenting for staged intervention with positive cardiac history OR Patient with stable CAD who received cardiac admission but does not report chest pain. OR Patient with stable CAD who has had a cardiac admission in the past. Patient is non-adherent to prescribed medication. The following exclusion criteria have been set for either safety concerns or concerns that patients will not be able to complete the protocol: inability to communicate in English or Spanish unwilling to be randomized or to have aspirin in a separate bottle if they use a pill box unavailability for the 1 month period of the study (including being unavailable by phone and/or traveling out of the country) medically unable to receive aspirin (e.g. allergy, contra-indicated, etc) deemed unable to comply with the protocol (either self selected or by indicating during screening that s/he could not complete all requested tasks). This includes patients with a level of cognitive impairment indicative of dementia, and patients with current alcohol or substance abuse. deemed to need immediate psychiatric assessment (e.g., must be hospitalized, or have some other psychiatric intervention conducted within 72 hours). active psychosis, bipolar disorder, or any overt personality disorder
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Karina W. Davidson, PhD
Organizational Affiliation
Columbia University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Columbia University
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Improving Medication Adherence in Post-ACS Patients

We'll reach out to this number within 24 hrs